{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"}],"units":"Participants"}],"description":"Percentage of participants who experienced failure to engraft (also called graft failure or graft rejection). Failure to engraft is defined as \\<5% donor chimerism and absence of relapse or any other reason for that chimerism value. All participants who met this criterion were included in this outcome measure.","groups":[{"description":"Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.","id":"OG000","title":"Mini-haplo BMT"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Cumulative incidence for the entire study, up to 11 years","title":"Graft Failure Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}